Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain

Eliazar Sabater (), Armando López-Guillermo, Antonio Rueda, Antonio Salar, Itziar Oyagüez and Juan Manuel Collar
Additional contact information
Eliazar Sabater: Pharmacoeconomics and Outcomes Research Iberia
Armando López-Guillermo: Hospital Clinic
Antonio Rueda: Hospital Costa del Sol
Antonio Salar: Hospital del Mar
Itziar Oyagüez: Pharmacoeconomics and Outcomes Research Iberia
Juan Manuel Collar: Mundipharma Pharmaceuticals

Applied Health Economics and Health Policy, 2016, vol. 14, issue 4, No 8, 465-477

Abstract: Abstract Background Follicular lymphoma (FL) is the second most common type of lymphoid cancer in Western Europe. Objective The aim of this study was to evaluate the cost utility of rituximab–bendamustine treatment compared with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) treatment as a first-line therapy for patients with advanced FL in Spain. Methods A Markov model was developed to estimate the cost effectiveness of rituximab–bendamustine compared with R-CHOP as first-line treatment for patients with advanced FL in the Spanish National Health System (NHS). Transitions between health states (progression-free, including induction and maintenance; first relapse; second relapse; and death) were allowed for the patient cohort in 4-week-long cycles. Clinical data for the extrapolation of progression-free survival curves were obtained from randomized trials. Mortality rates and utilities were obtained from the literature. Outcomes were measured as quality-adjusted life-years (QALYs). The total costs (€, 2013) included drug costs (ex-factory prices with mandatory deductions), disease management costs and adverse event-associated costs. Costs and outcomes were discounted at a 3 % annual rate. Probabilistic sensitivity analysis was performed using 10,000 Monte Carlo simulations to assess the model robustness. Results Treatment and administration costs during the induction phase were higher for rituximab–bendamustine (€17,671) than for R-CHOP (€11,850). At the end of the 25-year period, the rituximab–bendamustine first-line strategy had a total cost of €68,357 compared with €69,528 for R-CHOP. Health benefits were higher for rituximab–bendamustine treatment (10.31 QALYs) than for R-CHOP treatment (9.82 QALYs). In the probabilistic analysis, rituximab–bendamustine was the dominant strategy over treatment with R-CHOP in 53.4 % of the simulations. Conclusion First-line therapy with rituximab–bendamustine in FL patients was the dominant strategy over treatment with R-CHOP; it showed cost savings and higher health benefits for the Spanish NHS.

Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40258-016-0243-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:14:y:2016:i:4:d:10.1007_s40258-016-0243-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-016-0243-4

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().